Q1 EPS Estimate for Monopar Therapeutics Boosted by Analyst

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities research analysts at Brookline Capital Markets increased their Q1 2026 earnings per share estimates for Monopar Therapeutics in a research note issued to investors on Monday, March 30th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will earn ($0.80) per share for the quarter, up from their prior estimate of ($0.81). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Brookline Capital Markets also issued estimates for Monopar Therapeutics’ Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.81) EPS, Q4 2026 earnings at ($0.82) EPS and FY2026 earnings at ($3.23) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10).

A number of other brokerages have also weighed in on MNPR. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, January 22nd. Wall Street Zen lowered Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. BTIG Research reaffirmed a “buy” rating and set a $104.00 target price on shares of Monopar Therapeutics in a report on Monday, February 23rd. Finally, Morgan Stanley assumed coverage on Monopar Therapeutics in a report on Friday, January 9th. They set an “overweight” rating and a $115.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Monopar Therapeutics has a consensus rating of “Buy” and an average target price of $107.00.

Monopar Therapeutics Stock Performance

Shares of MNPR stock opened at $53.61 on Tuesday. The stock’s 50-day simple moving average is $57.25 and its 200-day simple moving average is $70.78. The firm has a market capitalization of $358.65 million, a PE ratio of -29.46 and a beta of 1.64. Monopar Therapeutics has a fifty-two week low of $26.06 and a fifty-two week high of $105.00.

Institutional Trading of Monopar Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd acquired a new stake in Monopar Therapeutics during the fourth quarter worth about $188,000. Virtu Financial LLC acquired a new stake in Monopar Therapeutics during the fourth quarter worth about $654,000. Invesco Ltd. acquired a new stake in Monopar Therapeutics during the fourth quarter worth about $219,000. ADAR1 Capital Management LLC grew its holdings in Monopar Therapeutics by 79.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company’s stock worth $15,274,000 after acquiring an additional 103,909 shares during the period. Finally, Virtus Investment Advisers LLC purchased a new position in Monopar Therapeutics during the fourth quarter worth approximately $233,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.